Physician profile
Fahima Nasreen
NPI 1841434289
$606.16
in general payments reported to CMS, 2019-2025
12 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $41.86 · 2023: $41.08 · 2024: $119 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.61 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $118.04 | 2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $82.54 | 2024-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $51.52 | 2024-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $48.49 | 2019 | |
| Travere Therapeutics, INC. | $27.44 | 2023 | |
| Janssen Pharmaceuticals, INC | $26.92 | 2020 | |
| Novo Nordisk INC | $25.79 | 2019-2020 | |
| Amarin Pharma, INC. | $16.57 | 2019 | |
| Daiichi Sankyo INC. | $16.02 | 2019 | |
| Merck Sharp & Dohme LLC | $13.64 | 2023 | Verquvo |
| Pfizer INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahima Nasreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.